Latest Kidney Disease News

Page 6 of 6
Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.
Ada Torres
Ada Torres
30 Apr 2025
PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.
Ada Torres
Ada Torres
17 Feb 2025
PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.
Ada Torres
Ada Torres
17 Feb 2025
PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.
Ada Torres
Ada Torres
10 Feb 2025
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.
Ada Torres
Ada Torres
31 Jan 2025
PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.
Ada Torres
Ada Torres
29 Jan 2025
Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.
Victor Sage
Victor Sage
28 Jan 2025
Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.
Sophie Babbage
Sophie Babbage
22 Jan 2025
Dimerix has reached a key milestone by enrolling the first paediatric patient aged 12-17 in its ACTION3 Phase 3 trial for DMX-200, advancing its potential treatment for childhood FSGS kidney disease.
Victor Sage
Victor Sage
16 Jan 2025